Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)

Benjamin Rolland1,2, Caroline Lions3†, Vincent Di Beo3†, Patrizia Carrieri3*, Nicolas Authier4, Tangui Barré3, Jessica Delorme4, Philippe Mathurin5, François Bailly6, Camelia Protopopescu3† and Fabienne Marcellin3†

Abstract

Background: Opioid agonist therapy (OAT) is associated with reduced injection, reduced HCV transmission, and more opportunities to initiate hepatitis C virus (HCV) treatment in people who use drugs (PWUD). We aimed to study the extent to which adherence to OAT was predictive of increased uptake of direct-acting antivirals (DAA) in PWUD with chronic HCV infection.

Methods: Using the French national healthcare system database, we targeted PWUD (i.e. with a history of OAT) who had chronic HCV infection and were eligible for DAA during 2014–2016. Adherence to OAT was computed as a time-varying variable expressing the proportion of days covered by OAT receipt, over any six-month interval before DAA receipt. We used a Cox proportional hazards model to estimate the association between adherence to OAT and the rate of DAA uptake after adjustment for age, sex, alcohol use disorder, socioeconomic status, and liver disease severity.

Results: Among the 22,615 persons included in the ANRS FANTASIO study, 3438 (15.2%) initiated DAA during the study period. After multivariable adjustment, adherence to OAT was associated with a higher rate of DAA initiation. However, this association was not linear, and only individuals on OAT for 20% or more of the time in the previous six-month period had a higher rate of DAA initiation (adjusted hazard ratio [95% confidence interval]: 1.28 [1.18–1.38]). Other variables associated with DAA initiation were male sex, older age, cirrhosis or liver cancer, and higher socioeconomic status.

Conclusions: Adherence to OAT is a major predictor of DAA initiation in PWUD living with chronic HCV infection in France. Our results also suggest that even moderate adherence to OAT can facilitate DAA uptake. Adequate HCV
Introduction
The availability and high effectiveness of direct-acting antivirals (DAA) for chronic hepatitis C virus infection (HCV) [1, 2] have led to new goals for HCV elimination worldwide.

The World Health Organization (WHO) has set a goal of eliminating HCV infection as a public health challenge by 2030, with a targeted 80% reduction in new infections, 65% reduction in mortality, diagnosis of 90% of people infected with HCV, and treatment of 80% of those diagnosed [3]. To achieve this goal, promoting universal screening and universal access to treatment for HCV is essential, as is identifying which factors can foster access to screening and treatment in the most exposed populations, in particular people who use drugs (PWUD).

In France, recent estimates showed a decrease in HCV infection prevalence in the general population between 2011 and 2016 from 0.42 to 0.30% [4]. Such a decrease has not been shown yet among PWUD, but modelling predictions suggest that HCV prevalence in the population under the current model of care in France will decrease to 11.6% by 2026 [5].

Since the 1990s, drug policy in France has constantly aimed to provide easier access to opioid agonist therapy (OAT) for PWUD by involving primary care professionals. This has resulted in approximately 80% OAT coverage in this population [6, 7]. Despite this high rate, adherence to OAT varies considerably and may affect their chances of initiating HCV treatment.

Structural and individual barriers to HCV treatment access have been highlighted in PWUD. The primary barrier they face is self-stigma, which is the consequence of layered stigma and discrimination in society and in the health setting [8] which is often underassessed in HCV research.

In this context, one possible way to encourage HCV treatment initiation in PWUD is through innovative models of care where low-threshold OAT would be a less-stigmatizing entry point.

It is important to note that OAT coverage in most countries where OAT is available is lower than in France [9] and OAT programs may tend to enroll the most motivated and adherent PWUD. Moreover, most studies exploring the relationship between OAT receipt and access to DAA [10–14] generally do not explore in real life to what extent adherence to OAT is predictive of access to HCV treatment.

In France, all health expenditures (i.e., drug prescriptions, dispensed drugs, hospital stays, etc.) are collected in the National System of Health Databases (Système National des Données de Santé, SNDS), which was developed by the national health insurance system. The SNDS allows the dynamic monitoring of geographic and individual health inequalities and can be used to analyze access to DAA. Using SNDS data, the ANRS FAN-TASIO study aimed to identify barriers and facilitators of access to DAA in the national population of chronic HCV patients treated with OAT. In a previous study from the project, we showed that in PWUD with chronic HCV infection, women [15], people with untreated alcohol use disorder (AUD) [16], and individuals living in areas with a limited number of hepatology specialists [17], were all more likely to have lower DAA uptake. In the present study, we aimed to investigate to what extent adherence to OAT was associated with a higher rate of DAA uptake in this population.

Materials and methods
The reporting of the study is based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [18] (see Additional file 1 for the completed STROBE checklist).

Data source
We used individual data from the SNDS, which collects anonymized data from all health expenditures (primarily reimbursement data for payments for drugs, clinical tests and procedures, as well as data from public and private hospitals) covering 98.8% of the country’s resident population. The SNDS also includes demographic characteristics (including dates of birth and death, and sex), complementary universal health cover status (Couverture Maladie Universelle complémentaire, CMU-C) which provides full healthcare expenditure cover for low-income groups and can be considered a proxy of social deprivation, and cover for long-term conditions (affection de longue durée, ALD), which provides full cover for individuals registered as having a costly chronic disease from a specific list [19].

In the present study, individuals with chronic HCV infection were identified using the International Classification of Diseases (ICD-10) (B18.2 code for chronic HCV infection). More precisely, persons registered with an HCV-related ALD or HCV-related hospitalization training for OAT prescribers together with interventions to ensure adherence to OAT will help improve DAA initiation rates and reach HCV elimination goals.

Keywords: Methadone, Buprenorphine, Hepatitis C, DAA, Drug use
between 2014 and 2016 were considered to have chronic HCV infection.

**Study population**
The present study population included all PWUD living in France with at least one OAT receipt—either methadone or buprenorphine—between 2012 and 2016, who were living with chronic HCV infection between 2014 (i.e., the year when DAA became available) and 2016, and who were therefore eligible for DAA treatment during this period.

**Study period**
For each participant, the study period covered the baseline (defined as 1 January 2014 for individuals diagnosed with HCV before this date, or the date of HCV diagnosis for the others) to the first DAA reimbursement, or censor on 31 December 2016, or death, whichever came first.

**Study outcome**
The study outcome was the time between the baseline and the first DAA-based HCV treatment receipt during the study period. The following DAA were considered: sofosbuvir, simeprevir, daclatasvir, sofosbuvir + ledipasvir, ombitasvir + ritonavir + boosted paritaprevir, and dasabuvir (with or without ribavirin).

**Variables**
For each six-month interval of follow-up over the study period, we used a time-varying variable representing adherence to OAT during those six months, computed as the percentage of time on OAT. We cumulated intervals of less than three months at the end of the study period (i.e., before the event or the censoring time) with the previous six-month interval.

The following other variables were included in the analyses as potential correlates of DAA treatment uptake: age (as a continuous variable), sex, AUD status, CMU-C status, and liver disease severity. AUD was defined as meeting at least one of the following criteria: AUD diagnosis during hospitalization for any cause (ICD-10 code F10), ALD for AUD, or any prescription of disulfiram, acamprosate, naltrexone, or naloxone, which were the only drugs approved for AUD treatment in France during the study period. We used a three-category variable for AUD status as follows: (1) no AUD, (2) untreated AUD, (3) treated AUD. Liver disease severity was characterized by cirrhosis (ICD-10 codes K74.3 to K74.6) or liver cancer (ICD-10 codes C22.0 to C22.4, C22.7 and C22.9). Accordingly, we built a three-category variable: (1) no cirrhosis and no liver cancer, (2) cirrhosis without liver cancer, and (3) liver cancer.

**Statistical analyses**
Descriptive statistics (numbers and percentages for categorical variables, mean and standard deviation (SD) for continuous variables) were used to present the characteristics of the study population. We used Cox proportional hazards models to estimate the association between adherence to OAT and time to DAA uptake, after adjustment for the following baseline characteristics: sex, age, CMU-C, liver disease severity and AUD status. The proportional hazards assumption was tested through a graphical assessment of the assumption of non-zero slope in a linear regression of the scaled Schoenfeld residuals as a function of time. Results of the models are provided as unadjusted hazard ratios (HR) and adjusted hazard ratios (aHR) for the univariable and multivariable models, respectively, and their 95% confidence intervals (CI). We performed a second analysis to identify factors associated with adherence to OAT, using a linear mixed-effects multivariable model.

**Results**
Between 2014 and 2016, 22,615 PWUD were identified as living with chronic HCV infection. Most were men (n = 17,682; 78.2%), with a mean (SD) age of 46.4 (7.3) years. Among them, 6496 (28.7%) were CMU-C recipients. In terms of AUD status, 18,247 (80.7%) did not have AUD, and 3445 (15.2%) had untreated AUD, while 923 (4.1%) had received treatment for AUD. Liver cirrhosis was reported by 776 (3.4%) persons, while 0.8% (n = 189) were diagnosed with liver cancer (Table 1). Most had less than 20% adherence to OAT (n = 17,224; 76.2%) during the first six months of follow-up. Only 356 (1.6%) individuals were adherent to OAT over the entire study period.

The results of the Cox models are presented in Table 1. Among the 22,615 persons included, 3438 (15.2%) initiated DAA treatment during the study period. The relationship between adherence to OAT and rate of DAA uptake was not linear. Individuals with adherence to OAT ≥20% in the previous six months had a higher likelihood of DAA uptake (Table 1). In the multivariable Cox model, adherence to OAT ≥20% was associated with a higher rate of DAA uptake (aHR [95% CI] = 1.28 [1.18–1.38]). All tested variables, except for AUD status, were significantly associated with DAA uptake. Older patients (1.03 [1.03–1.04] per 1-year age increase) and patients with cirrhosis and liver cancer (3.99 [3.50–4.54] and 3.03 [2.27–4.06], respectively) had a higher likelihood of DAA treatment uptake compared to other patients (Table 1).
By contrast, female sex (0.82 [0.75–0.90]) and social deprivation (receiving CMU-C) (0.91 [0.84–0.98]) were associated with lower DAA uptake rates. The results showed no indication that the proportionality of hazards assumption was violated.

Linear mixed-effects multivariable regression showed that factors associated with adherence to OAT were female sex (adjusted regression coefficient [95% CI] = 1.35 [0.57; 2.13]) and younger age (−0.09 [−0.13; −0.04] per 1-year increase). No association was found between receiving CMU-C, liver disease severity, AUD status and adherence to OAT (Table 2).

**Discussion**

This is the first French nationwide study to explore to what extent adherence to OAT in the previous six months influences the rate of DAA uptake. The main result was that the presence of a threshold effect. More specifically, individuals who had received OAT for more than 20% of the time in the previous six months were more likely to initiate DAA. As OAT prescription is monthly in France, 20% of the time corresponds to two or more OAT prescriptions in the previous six months. The second important result is that only 15% of PWUD with chronic HCV infection in our study received DAA treatment between 2014 and 2016, suggesting that treating strategies were suboptimal in this population. Our results are consistent with previous studies conducted in other countries which have already highlighted that OAT access is a major predictor of DAA uptake [11, 20, 21]. Interestingly, women, as demonstrated elsewhere [15], had fewer opportunities to initiate DAA despite tending to be more adherent to OAT. This indirectly suggests that other barriers, unrelated to OAT access and success, may interfere with opportunities for DAA initiation in women. We wonder whether this association between

---

**Table 1** Characteristics of PWUD with chronic hepatitis C and factors associated with DAA uptake, univariable and multivariable Cox regression (ANRS FANTASIO study; 22,615 patients)

| Variables | N (%) or Mean (SD) at inclusion | Univariable analyses | Multivariable analysis |
|-----------|--------------------------------|----------------------|------------------------|
|           |                                | HR [95% CI]          | p-value                | aHR [95% CI] | p-value |
| Sex       |                                |                      |                        |             |        |
| Male (ref.) | 17,682 (78.2)                | 1                    |                        | 1           |        |
| Female    | 4933 (21.8)                  | 0.79 [0.72–0.86]     | < 0.001                | 0.82 [0.75–0.90] | < 0.001 |
| Age (per 1-year increase) | 46.4 (7.3) | 1.04 [1.03–1.05] | < 0.001                | 1.03 [1.03–1.04] | < 0.001 |
| Receiving CMU-C |                                |                      |                        |             |        |
| No (ref.) | 16,119 (71.3)                | 1                    |                        | 1           |        |
| Yes       | 6496 (28.7)                  | 0.82 [0.76–0.88]     | < 0.001                | 0.91 [0.84–0.98] | 0.018  |
| Liver disease severity |                                |                      |                        |             |        |
| No cirrhosis and no liver cancer (ref.) | 21,650 (95.7) | 1 |                        | 1           |        |
| Cirrhosis without liver cancer | 776 (3.4) | 4.33 [3.83–4.90] | < 0.001                | 3.99 [3.50–4.54] | < 0.001 |
| Liver cancer | 189 (0.8) | 3.78 [3.25–5.03] | < 0.001                | 3.04 [2.27–4.06] | < 0.001 |
| Alcohol use disorder (AUD) |                                |                      |                        |             |        |
| No AUD (ref.) | 18,247 (80.7) | 1 |                        | 1           |        |
| Untreated AUD | 3445 (15.2) | 1.06 [0.96–1.17] | 0.224                  | 0.92 [0.83–1.01] | 0.090  |
| Treated AUD | 923 (4.1)                   | 1.08 [0.91–1.27]     | 0.369                  | 1.06 [0.89–1.26] | 0.505  |
| Adherence to OAT* |                                |                      |                        |             |        |
| Less than 20% (ref.) | 17,224 (76.2) | 1 |                        | 1           |        |
| 20% and more | 5391 (23.8) | 1.28 [1.19–1.38] | < 0.001                | 1.28 [1.18–1.38] | < 0.001 |
| 0% (ref.) | 13,081 (57.8)                | 1                    |                        | 1           |        |
| 1–19%     | 4143 (18.3)                  | 0.94 [0.86–1.03]     | 0.205                  | –           | –      |
| 20–39%    | 2126 (9.4)                   | 1.35 [1.21–1.51]     | < 0.001                | –           | –      |
| 40–59%    | 1077 (4.8)                   | 1.37 [1.19–1.57]     | < 0.001                | –           | –      |
| 60%+      | 2188 (9.7)                   | 1.12 [0.99–1.26]     | 0.069                  | –           | –      |

aHR, Adjusted hazard ratio; CI, confidence interval; CMU-C, complementary universal health coverage status (Couverture Maladie Universelle – complémentaire); DAA, direct-acting antivirals; HR, hazard ratio; OAT, opioid agonist therapy; PWUD, people who use drugs; SD, standard deviation

*Time-varying variable, the numbers and percentages are calculated during the first six months of follow-up
sex and DAA uptake indirectly expresses discrimination experienced by women who use drugs [8]. This discrimination is associated with self-stigma, which is a known predictor of care avoidance. Another important result is that individuals from socially deprived groups (i.e., receiving CMU-C) tended to have lower DAA uptake rates despite having similar adherence to OAT as others. This would suggest—as was the case for women—that other barriers to DAA initiation are involved, such as prioritizing economic concerns over HCV cure. The effect of age and sex on DAA uptake have already been outlined in previous studies [22]. Social deprivation (captured by the CMU-C indicator) was associated with a lower rate of DAA uptake [23]. Unsurprisingly, greater liver disease severity was associated with a higher rate of DAA uptake.

The considerable variability in adherence to OAT, which we found using French administrative data, may be due to high accessibility and coverage of this treatment in the country. Community pharmacies dispense OAT to a variety of patient profiles, including individuals less motivated to take it. Moreover, the entry point for OAT treatment may influence retention, as demonstrated in a randomized trial conducted in France which showed lower retention rates in individuals who were randomized into specialized care settings compared to those randomized into primary care [24].

Overall, our results suggest that strategies to improve adherence to OAT in HCV-infected PWUD should be a key element for improving DAA uptake rates in this population.

The present study had limitations. First, the study population did not include people with no access to the French health insurance system. However, the latter comprise only 1.2% of the national population [10]. Second, we did not have information on drug use, and receiving OAT was used as a proxy for being a PWUD; however, this can be considered an acceptable approximation, given that 80% of the PWUD population in France receive OAT. Third, OAT can be initiated (but not necessarily followed up) in specialized centers whose data are not collected in the French health insurance system database. However, 90% of French OAT prescriptions are delivered in community pharmacies [25], suggesting that the health insurance database captures most of the population receiving OAT.

In conclusion, adherence to OAT is a major predictor of DAA initiation in PWUD living with chronic HCV infection in France. Our results also suggest that even moderate adherence to OAT can facilitate DAA uptake. This indirectly suggests that adherence to OAT should not be neglected in future analyses estimating the association between receiving OAT and access to treatment for any co-occurring condition in PWUD. Adequate HCV training for OAT prescribers together with interventions to ensure adherence to OAT will help improve DAA initiation rates and reach HCV elimination goals.

### Table 2 Characteristics of PWUD with chronic hepatitis C and factors associated with adherence to OAT in the previous six months, univariable and multivariable mixed effects linear regression models (ANRS FANTASIO study; 22,615 patients)

| Variables                                | Univariable analyses | Multivariable analysis |
|------------------------------------------|----------------------|------------------------|
|                                          | Coef [95% CI]        | p-value                | aCoef [95% CI]        | p-value |
| Sex                                      |                      |                        |                       |         |
| Male (ref.)                              | 0                    | 0                      | 0                     | 0       |
| Female                                   | 1.45 [0.67; 2.23]    | <0.001                 | 1.35 [0.57; 2.13]     | 0.001   |
| Age (per 1-year increase)                | −0.09 [−0.13; −0.05] | <0.001                 | −0.09 [−0.13; −0.04]  | <0.001  |
| Receiving CMU-C                          |                      |                        |                       |         |
| No (ref.)                                | 0                    | 0                      | 0                     | 0       |
| Yes                                      | 0.75 [0.05; 1.44]    | 0.035                  | 0.52 [−0.18; 1.22]    | 0.147   |
| Liver disease severity                   |                      |                        |                       |         |
| No cirrhosis and no liver cancer (ref.)  | 0                    | 0                      | 0                     | 0       |
| Cirrhosis without liver cancer           | 1.23 [−0.55; 3.00]   | 0.176                  | 1.79 [−0.01; 3.59]    | 0.051   |
| Liver cancer                             | 0.39 [−2.69; 3.47]   | 0.804                  | 1.32 [−1.79; 4.42]    | 0.406   |
| Alcohol use disorder (AUD)               |                      |                        |                       |         |
| No (ref.)                                | 0                    | 0                      | 0                     | 0       |
| Yes                                      | −0.58 [−1.34; 0.18]  | 0.132                  | −0.77 [−1.53; 0.01]   | 0.051   |

aCoef, Adjusted regression coefficient; CI, confidence interval; CMU-C, complementary universal health coverage status (Couverture Maladie Universelle – complémentaire); Coef, regression coefficient; OAT, opioid agonist therapy; PWUD, people who use drugs.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12954-022-00702-9.

Additional file 1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.

Acknowledgements

The authors thank Jude Sweeney for his careful English editing of the manuscript.

Author contributions

BR, PNC, FM and CP designed the present study. BR, CL and PC wrote the first draft of the manuscript. JD and NA extracted and provided the data from the SNDS. VDB/CP conducted/supervised the statistical analyses. All authors revised the various drafts of the manuscript including its final version. All authors read and approved the final manuscript.

Funding

The FANTASIO ANRS study was funded by a national public grant from the "Agence nationale de recherches sur le sida et les hépatites virales/Maladies infectieuses émergentes" (ANRS/MIE, Contrat d’Initiation #2018.03.12) and from MSD France.

Availability of data and materials

Data belong to the French Claims database and are not allowed to be shared to other research teams. The datasets generated and/or analysed during the current study are not publicly available because data are not public and access to data is currently possible only to French researchers upon request to SNDS for a specific research project.

Declarations

Ethics approval and consent to participate

The healthcare data of all French citizens are automatically pseudonymized and integrated into the SNDS. The use of the SNDS data for FANTASIO was approved by the National Institute of Health Data (Institut National des Données de Santé, INDS) (IDS no. 176, issued on 2 March 2016) and the National Commission on Informatics and Freedoms (Commission nationale de l’informatique et des libertés, CNIL) (no. 1946535 issued on 4 August 2016).

Competing interests

BR received a research grant from MSD for this study and received lecture and consultancy fees from Gilead and Abbvie. BR received a research grant from MSD for this study and received lecture and consultancy fees from Gilead and Abbvie. PC received research grants from BR received a research grant from MSD for this study and received lecture and consultancy fees from Gilead and Abbvie. PC received research grants from BR received a research grant from MSD for this study and received lecture and consultancy fees from Gilead and Abbvie. The other authors have no competing interest to disclose.

Author details

1. Service Universitaire d’Addictologie de Lyon (SUAL), Hospices Civils de Lyon, CH Le Vinatier, Lyon, France. 2. PsyR2 CRNL, UCBT 1, INSERM U1028, CNRS UMR5292, Bron, France. 3. Aix Marseille Univ, Inserm, IRD, SESSIM, Sciences Economiques et Sociales de la Sante & Traitement de l’Information Médicale, ISSPAM, Marseille, France. 4. CHU Clermont-Ferrand, Neuro-Dol, Service de Pharmacologie Médicale, Centres Addictologie et Pharmaco-gérontologie, Université Clermont Auvergne, Clermont-Ferrand, France. 5. Service d’hépatologie et d’addictologie, Groupe Hospitalier Nord, Hôpital de La Croix-Rousse, Lyon, France.

Received: 22 May 2022 Accepted: 29 September 2022 Published online: 27 October 2022

References

1. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.
2. Sahaykan Y, Lee-Kim V, Brenmer KE, Bielecki JM, Krahm MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: Systematic review and meta-analysis. J Viral Hepat. 2021;28(5):739–54.
3. WHO. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
4. Brouard C, Pillonel J, Bousmac M, de Ledenghin V, Rachas A, Silvain C, et al. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long. BMC Infect Dis. 2020;20(1):759.
5. Cousien A, Leclerc P, Morissette C, Bruneau J, Roy E, Tran VC, et al. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montreal, Canada: a modelling study. BMC Infect Dis. 2017;17(1):162.
6. Roux P, Rojas Castro D, Ndiaye K, Debrus M, Protopopescu C, Le Gall JM, et al. Increased uptake of HCV testing through a community-based educational intervention in difficult-to-reach people who inject drugs: results from the ANRS-AERLI study. PLOS ONE. 2016;11(6):e0157062.
7. Weill-Barillat L, Pillonel J, Semaillle C, Leon L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV serorevelopment, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64(4):301–12.
8. Karlsen TH, Sheron N, Zelber-Sagi S, Carriere P, Dusheiko G, Bugianesi E, et al. The EASL-lancer liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61–116.
9. Larney S, Peacock C, Leung J, Colledge H, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–20.
10. Gibbs D, Price O, Grebely J, Larney S, Sutherland R, Read P, et al. Hepatitis C virus cascade of care among people who inject drugs in Australia: factors associated with testing and treatment in a universal healthcare system. Drug Alcohol Depend. 2021;238:109050.
11. Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(1):e107–18.
12. T.L, Socias ME, Wood E, Milloy MJ, Nosova E, DeBeck K, et al. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLOS ONE. 2018;13(3):e0194162.
13. Valerio H, Alavi M, Silk D, Teloar C, Martinello M, Milat A, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS engage study. Clin Infect Dis. 2021;73(1):e69–78.
14. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.
15. Rojas Rojas T, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, et al. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAAs era: the ANRS FANTASIO project. Int J Drug Policy. 2019;72:61–8.
16. Barre T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, et al. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Addiction. 2020;115(3):573–82.
17. Marcellin F, Roux P, Lazarus JV, Rolland E, Carriere P, France removes hepatitis C treatment prescriber restrictions-But what is the impact of the delay for key populations? Liver Int. 2019;39(2):2418–9.
18. Noah N. The STROBE initiative: STrengthening the reporting of Observational studies in Epidemiology (STROBE). Epidemiol Infect. 2008;136(7):885.
de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.

20. Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: the LiveRLife study. J Viral Hepat. 2020;27(3):281–93.

21. Bartlett SR, Wong S, Yu A, Pearce M, Macisaac J, Nouch S, et al. The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from the direct-acting antiviral (DAA) era: a population-based study. Clin Infect Dis. 2022;74(4):575–83.

22. Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle. Wash Drug Alcohol Depend. 2021;220:108525.

23. Karmarkar T, Padula WV, Gaskin DJ, Watson E, Rodriguez CV. Characteristics associated with time-to-treatment initiation for chronic Hepatitis C with new direct acting antivirals. Pharmacoepidemiol Drug Saf. 2021;30(1):86–96.

24. Carrieri PM, Michel L, Lions C, Cohen J, Vray M, Mora M, et al. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLOS ONE. 2014;9(11):e112328.

25. A.C. B. C. C. Les traitements de substitution aux opiacés en France: données récentes/Opiate substitution treatments in France: recent data. 2014.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.